CA2222813A1 - Variants du gene preseniline 2 - Google Patents
Variants du gene preseniline 2 Download PDFInfo
- Publication number
- CA2222813A1 CA2222813A1 CA002222813A CA2222813A CA2222813A1 CA 2222813 A1 CA2222813 A1 CA 2222813A1 CA 002222813 A CA002222813 A CA 002222813A CA 2222813 A CA2222813 A CA 2222813A CA 2222813 A1 CA2222813 A1 CA 2222813A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- gene
- strandedness
- topology
- sense
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010036908 Presenilin-2 Proteins 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 4
- 238000012163 sequencing technique Methods 0.000 claims description 2
- 102000012419 Presenilin-2 Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 66
- 230000000692 anti-sense effect Effects 0.000 description 52
- 108020004707 nucleic acids Proteins 0.000 description 51
- 102000039446 nucleic acids Human genes 0.000 description 51
- 150000007523 nucleic acids Chemical class 0.000 description 51
- 238000003752 polymerase chain reaction Methods 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 201000010099 disease Diseases 0.000 description 17
- 239000002299 complementary DNA Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 108700028369 Alleles Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 108700024394 Exon Proteins 0.000 description 11
- 102100022033 Presenilin-1 Human genes 0.000 description 9
- 108010036933 Presenilin-1 Proteins 0.000 description 9
- 230000035772 mutation Effects 0.000 description 9
- 101000617546 Homo sapiens Presenilin-2 Proteins 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 102100022036 Presenilin-2 Human genes 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 6
- 235000001014 amino acid Nutrition 0.000 description 6
- 229940024606 amino acid Drugs 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- UVJPCPROJZIFAV-YAUCMBIBSA-N alpha-L-Rhap-(1->3)-[alpha-L-Rhap-(1->3)-beta-D-Glcp-(1->4)]-alpha-D-Glcp-(1->2)-alpha-D-Glcp Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@@H]([C@H](O)[C@@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H]1O UVJPCPROJZIFAV-YAUCMBIBSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 108020003589 5' Untranslated Regions Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000282320 Panthera leo Species 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000015756 familial Alzheimer disease Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 102100025230 2-amino-3-ketobutyrate coenzyme A ligase, mitochondrial Human genes 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- 108010087522 Aeromonas hydrophilia lipase-acyltransferase Proteins 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- RGTVXXNMOGHRAY-WDSKDSINSA-N Cys-Arg Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N RGTVXXNMOGHRAY-WDSKDSINSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 101150105088 Dele1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- QTANTQQOYSUMLC-UHFFFAOYSA-O Ethidium cation Chemical compound C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 QTANTQQOYSUMLC-UHFFFAOYSA-O 0.000 description 1
- 101000938391 Homo sapiens Transmembrane protein Proteins 0.000 description 1
- 101001064119 Homo sapiens Truncated surface protein Proteins 0.000 description 1
- 101001064124 Homo sapiens Truncated surface protein Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical class C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 241000353097 Molva molva Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150079937 NEUROD1 gene Proteins 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000009141 biological interaction Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000003485 founder effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- -1 i.e. Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000012301 transgenic model Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
L'invention concerne des variants du gène préséniline 2, ainsi que des méthodes permettant d'utiliser lesdits variants pour le diagnostic de la maladie d'Alzheimer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1486096P | 1996-04-04 | 1996-04-04 | |
| US60/014,860 | 1996-04-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2222813A1 true CA2222813A1 (fr) | 1997-10-16 |
Family
ID=21768192
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002222813A Abandoned CA2222813A1 (fr) | 1996-04-04 | 1997-03-20 | Variants du gene preseniline 2 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0833947A4 (fr) |
| JP (1) | JP2002515740A (fr) |
| AU (1) | AU2541497A (fr) |
| CA (1) | CA2222813A1 (fr) |
| WO (1) | WO1997038133A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999060122A1 (fr) * | 1998-05-21 | 1999-11-25 | Tanabe Seiyaku Co., Ltd. | Methode d'examen des maladies du snc et de criblage des remedes associes |
| GB0106051D0 (en) * | 2001-03-12 | 2001-05-02 | Isis Innovation | Diagnostic screens for alzheimer's disease |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE182900T1 (de) * | 1992-03-20 | 1999-08-15 | Innogenetics Nv | Mutierte form von dem beta-amyloidprecursor proteine gen |
| US5986054A (en) * | 1995-04-28 | 1999-11-16 | The Hospital For Sick Children, Hsc Research And Development Limited Partnership | Genetic sequences and proteins related to alzheimer's disease |
-
1997
- 1997-03-20 EP EP97916930A patent/EP0833947A4/fr not_active Withdrawn
- 1997-03-20 JP JP53622997A patent/JP2002515740A/ja active Pending
- 1997-03-20 AU AU25414/97A patent/AU2541497A/en not_active Abandoned
- 1997-03-20 WO PCT/US1997/004683 patent/WO1997038133A1/fr not_active Application Discontinuation
- 1997-03-20 CA CA002222813A patent/CA2222813A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO1997038133A1 (fr) | 1997-10-16 |
| JP2002515740A (ja) | 2002-05-28 |
| EP0833947A4 (fr) | 2003-07-02 |
| AU2541497A (en) | 1997-10-29 |
| EP0833947A1 (fr) | 1998-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017267184B2 (en) | Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy | |
| AU735756B2 (en) | Large scale genotyping of diseases and a diagnostic test for spinocerebellar ataxia type 6 | |
| CN107941681B (zh) | 鉴定生物样品中定量细胞组成的方法 | |
| US6429011B1 (en) | Neuronal apoptosis inhibitor protein gene sequence and mutations causative of spinal muscular atrophy | |
| DK2199411T3 (en) | Epigenetic markers for the identification of CD3-positive T lymphocytes | |
| CN107223159A (zh) | 源自特定细胞类型的dna的检测及相关方法 | |
| AU2016351889A1 (en) | Detection of foetal chromosomal aneuploidies using DNA regions that are differentially methylated between the foetus and the pregnant female | |
| CA2404448C (fr) | Genes impliques dans les maladies inflammatoires de l'intestin et leur utilisation | |
| AU2017302611B2 (en) | GPR156 variants and uses thereof | |
| CA2376666C (fr) | Polymorphismes du gene mdr-1 humain et leur utilisation dans des applications diagnostiques et therapeutiques | |
| US6262334B1 (en) | Human genes and expression products: II | |
| CA2454073C (fr) | Mutations au niveau de canaux ioniques | |
| GB2424886A (en) | Polynucleotide primers against epidermal growth factor receptor and method of detecting gene mutations | |
| KR20230173074A (ko) | 향상된 이종이식편 생존 및 관용을 위한 하나 이상의 변형된 유전자를 갖는 세포, 조직, 기관, 및 동물 | |
| AU775183B2 (en) | Nucleic acids, kits, and methods for the diagnosis, prognosis and treatment of glaucoma and related disorders | |
| US20020137077A1 (en) | Genes regulated in activated T cells | |
| JP2004515209A5 (fr) | ||
| CA2222813A1 (fr) | Variants du gene preseniline 2 | |
| PL194248B1 (pl) | Cząsteczka kwasu nukleinowego kodująca polipeptydy, ludzkie białko wzrostu kodowane przez cząsteczkę DNA, cDNA kodujący ludzkie białko wzrostu, środek farmaceutyczny, zastosowanie ludzkiego białka wzrostu oraz sekwencji DNA, sposób określania niskiego wzrostu, sposób identyfikacji defektu genetycznego, komórki transformowane sekwencją DNA, układ testowy i sposób identyfikacji lub badań przesiewowych, wektor ekspresyjny oraz zastosowanie ludzkichbiałek wzrostu | |
| US6448041B1 (en) | Colon cancer marker | |
| KR20230051478A (ko) | 3등급 자궁경부 상피 신생물(cin3) 및/또는 암을 검출하고 예측하기 위한 방법 | |
| WO2004111272A2 (fr) | Polymorphisme du gene humain nbs1 servant au diagnostic d'une predisposition hereditaire au cancer | |
| CA2376361A1 (fr) | Gene 3 lie au cancer de la prostate (pg-3) et marqueurs bialleliques | |
| CA2421747A1 (fr) | Polymorphismes associes a l'arythmie cardiaque | |
| TW202313972A (zh) | 新ｎｒｇ１融合物、融合接合處及檢測彼等之方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |